Search bioRxiv⌕ Search

Biology subjects

Julvez, J.

Publications and source records attributed to Julvez, J..

4 recordsLinked to original sources

Enhancing the accuracy of genome-scale metabolic models with kinetic information

Metabolic models can be used to analyze and predict cellular features such as growth, gene essentiality, and product formation. There are several metabolic models but two of the main types are the constraint-based models and the kinetic models. Constraint-based models usually account for a large subset of the metabolic reactions of the organism and, in addition to the reaction stoichiometry, these models can accommodate gene regulation and constant flux bounds of the reactions. Constraint-based models are mostly limited to the steady state and it is challenging to optimize competing objective functions. On the other hand, kinetic models contain detailed kinetic information of a relatively small subset of metabolic reactions; thus, they can only provide precise predictions of a reduced part of an organisms metabolism. We propose an approach that combines these two types of modeling to enrich metabolic genome-scale constraint-based models by re-defining their flux bounds. We apply our approach to the constraint-based model of E. coli, both as a wild-type and when genetically modified to produce citramalate. We show that the enriched model has more realistic reaction flux boundaries. We also resolve a bifurcation of fluxes between growth and citramalate production present in the genetically modified model by fixing the growth rate to the value computed according to kinetic information, enabling us to predict the rate of citramalate production. IMPORTANCEThe investigation addressed in this manuscript is crucial for biotechnology and metabolic engineering, as it enhances the predictive power of metabolic models, which are essential tools in these disciplines. Constraint-based metabolic models, while comprehensive, are limited by their steady-state assumption and difficulty in optimizing competing objectives, whereas kinetic models, though detailed, only cover a small subset of reactions. By integrating these two approaches, our novel methodology refines flux bounds in genome-scale models, leading to more accurate and realistic metabolic predictions. Key highlights include improved predictive accuracy through more realistic flux boundaries, application to both wild-type and genetically modified E. coli for citramalate production, successful resolution of the bifurcation between growth and product formation, and broad applicability to other organisms and metabolic engineering projects, paving the way for more efficient bioproduction processes.

systems biology↗

Mycobacterial Metabolic Model Development for Drug Target Identification

Antibiotic resistance is increasing at an alarming rate, and three related mycobacteria are the source of widespread infections in humans. According to the World Health Organization, Mycobacterium leprae, which causes leprosy, is still endemic in tropical countries; Mycobacterium tuberculosis is the second largest infectious disease killer worldwide after COVID-19; Mycobacteroides abscessus, a group of non-tuberculous mycobacteria, causes lung infections and other health-care-associated infections in humans. Due to the rise in resistance to common antibacterial drugs, it is critical to develop alternatives to traditional treatment procedures. Furthermore, an understanding of the biochemical mechanisms underlying pathogenic evolution is important for the treatment and management of these diseased conditions. In this study, metabolic models have been developed for two bacterial pathogens, M. leprae, and M. abscessus, and a new computational tool has been used to identify potential drug targets, which are referred to as bottleneck reactions. The genes, reactions, and pathways in each of these organisms have been highlighted; the potential drug targets can be further explored as broad-spectrum antibacterials and the unique drug targets to each pathogen are significant for precision medicine initiatives. The models and associating datasets are available in GigaScience and the following repositories: O_LIM. abscessus O_LIBiomodels: https://www.ebi.ac.uk/biomodels/MODEL2203300002 C_LIO_LIhttps://www.patmedb.org/Bacteria/Mabscessus C_LI C_LIO_LIM. leprae O_LIBiomodels: https://www.ebi.ac.uk/biomodels/MODEL2203300001 C_LIO_LIhttps://www.patmedb.org/Bacteria/Mleprae C_LI C_LI

systems biology↗

Association between DNA methylation and ADHD symptoms from birth to school age: A prospective meta-analysis

Attention-deficit and hyperactivity disorder (ADHD) is a common childhood disorder with a substantial genetic component. However, the extent to which epigenetic mechanisms play a role in the etiology of the disorder is not known. We performed epigenome-wide association studies (EWAS) within the Pregnancy And Childhood Epigenetics (PACE) Consortium to identify DNA methylation sites associated with ADHD symptoms at two methylation assessment periods: birth and school-age. We examined associations of DNA methylation in cord blood with repeatedly assessed ADHD symptoms (age range 4-15 years) in 2477 children from five cohorts and DNA methylation at school-age with concurrent ADHD symptoms (age 7-11 years) in 2374 children from ten cohorts. CpGs identified with nominal significance (p<0.05) in either of the EWAS were correlated between timepoints ({rho}=0.30), suggesting overlap in associations, however, top signals were very different. At birth, we identified nine CpGs that were associated with later ADHD symptoms (P<1*10-7), including ERC2 and CREB5. Peripheral blood DNA methylation at one of these CpGs (cg01271805 located in the promotor region of ERC2, which regulates neurotransmitter release) was previously associated with brain methylation. Another (cg25520701) lies within the gene body of CREB5, which was associated with neurite outgrowth and an ADHD diagnosis in previous studies. In contrast, at school-age, no CpGs were associated with ADHD with P<1*10-7. In conclusion, we found evidence in this study that DNA methylation at birth is associated with ADHD. Future studies are needed to confirm the utility of methylation variation as biomarker and its involvement in causal pathways.

genetics↗

Comparative analyses of metabolic pathways in mycobacteria: Insights into the identification and characterisation of new drug targets in M. tuberculosis, M. leprae and M. abscessus

Three related mycobacteria are the cause of widespread infections in man and are the focus of intense research and drug-discovery efforts in the face of growing antimicrobial resistance. Mycobacterium tuberculosis, the causative agent of tuberculosis, is currently one of the top ten causes of death in the world according to WHO; M. abscessus, a group of non-tuberculous mycobacteria causes lung infections and other opportunistic infections in humans; and M. leprae, the causative agent of leprosy, remains endemic in tropical countries. There is an urgent need to design alternatives to conventional treatment strategies, due to the increase in resistance to standard antibacterials. In this study, we present a comparative analysis of chokepoint and essentiality datasets that will provide insight into the development of new treatment regimes. We illustrate the key metabolic pathways shared between these three organisms and identify drug targets with a wide metabolic impact that are common to the three species. We demonstrate that 72% of the chokepoint enzymes are proteins essential to Mycobacterium tuberculosis. We show also that 78% of the drug targets, prioritized based on their presence in multiple paths on the metabolic network, are present in pathways shared by M. tuberculosis, M. leprae and M. abscessus, including biosynthesis of amino acids, carbohydrates, cell structures, fatty acid and lipid biosynthesis. A further 17% is found in the prioritised pathways shared between M. tuberculosis and M. abscessus. We have performed comparative structure modelling of potential drug targets identified using our analysis in order to assess druggability and demonstrate the importance of chokepoint analysis in terms of drug target identification. AUTHOR SUMMARYComputer simulation studies to design new drugs against mycobacteria

bioinformatics↗